Di Liu, Ming Xia, Chang Wang, Xuejing Zhu, Guochun Chen and Hong Liu* Pages 1 - 7 ( 7 )
Introduction: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.
Case Representation: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.
Discussion: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.
Conclusion: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.
Proliferative glomerulonephritis with monoclonal IgG deposits, rituximab, tacrolimus, renal outcome, case report, steroids.